# Thrombus Treatment Market > Thrombus Treatment Market Research Report Information by Type (Atrial Thrombus [Right Atrial Thrombus and Left Atrial Thrombus] and Venous Thrombus), by Treatment (Medical Therapy [Antiplatelets, Anticoagulants, and Thrombolytics], Surgery, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest of the World) - Forecast till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.57% - **2024:** $ 40.27 Billion - **2025:** $ 42.92 Billion - **2035:** $ 81.11 Billion - **Key Players:** Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), Pfizer Inc. (US), Novartis AG (CH), Merck & Co., Inc. (US) **Report ID:** MRFR/HC/9934-CR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/thrombus-treatment-market-11453 --- ## Market Summary ## **Thrombus Treatment Market Overview** Thrombus Treatment Market Size was valued at USD 39.43 Billion in 2023. The Global Thrombus Treatment industry is projected to grow from USD 40.27 Billion in 2024 to USD 70.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.57% during the forecast period (2024 - 2032). The factors influencing the market growth are increasing incidence of trauma cases and rising adoption of sedentary lifestyle are bolstering the market growth. ## **Thrombus Treatment Market Trends** Trauma is considered as one of the most common causes for the formation of thrombus in the lower extremities. When any blood vessels get damages, the surround blood thickens and forms a clot. Hence, blood vessel damage due to trauma can cause the formation of a thrombus. The increases number trauma cases, especially road accidents have led to the increase in demand for thrombus treatment. According to the WHO in June 2022, around 1.3 million people lose their lives due to road accidents globally. Additionally, 20-30 trillion people suffer non-fatal injuries per year. Over 90% of such fatalities occur in low- and middle-income countries which is expected to drive the market of thrombus treatment significantly in those countries with a significant growth rate. Additionally, there were 178 million new fracture cases registered in 2019 globally which had increased by 33.4% since 1990. The total prevalence of acute and long-term fracture symptoms had reached 455 million in 2910 with an increase of 67.5% since 1990. Fracture is another common cause for thrombosis. Hence, the increasing incidence of trauma cases is driving market demand for the Thrombus Treatment. ## **Thrombus Treatment Market Segment Insights** ### **Thrombus Treatment Type Insights** The market segments of thrombus treatment, based on type, includes atrial thrombus and venous thrombus. The atrial thrombus bifurcated into right atrial thrombus and left atrial thrombus.  Venous thrombus held the largest market share and contributed USD 22.58 billion in 2021 owing to the interaction between obesity and other risk factors doubles the risk of venous thrombus. The World Obesity Atlas 2022 stated that 1 billion people globally i.e., 1 in 5 women and 1 in 7 men will have diabetes by 2030. Therefore, the increase in obesity in the coming years will lead to venous thrombosis, fueling the venous thrombosis segment market. ### **Thrombus Treatment Treatment Insights** The Thrombus Treatment Market data has been segmented, based on treatment, by medical therapy, surgery, and others. The medical therapy segment has been segmented into antiplatelets, anticoagulants, and thrombolytics. Medical therapy held the largest market share and contributed USD 34.36 billion in 2021 and the surgery anticipated to register the highest CAGR of 7.78% from 2024 to 2032. The most common antiplatelets used to treat thrombus include acetylsalicylic acid (ASA), clopidogrel, prasugrel, and [ticagrelor](../../../reports/ticagrelor-market-820). Acetylsalicylic acid includes aspirin, which is effective in treating thrombosis. December 2021, Johnson & Johnson's (US) subsidiary Janssen Pharmaceutical Companies (Belgium) announced that the US Food and Drug Administration (FDA) had approved its two paediatric indications for XARELTO. **Figure 2: Thrombus Treatment Market, by Treatment, 2022 & 2032 (USD Billion)** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **Thrombus Treatment Regional Insights** By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America held the largest market share and contributed USD 16.19 billion in 2021 owing to developed healthcare infrastructure, research grants for producing safe and effective thrombus treatment, the growing aged and obese population in the region. For instance, according to the World Health Organization (WHO) 2021, the North America population over 80 years will triple from 143 million in 2019 to 426 million in 2050. Therefore, the growing aged and obese population supports the market growth of thrombus treatment. Further, the major countries studied are: The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 3: THROMBUS TREATMENT MARKET BY REGION 2022 & 2032** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review Europe thrombus treatment market accounts for the second-largest market share owing to growing research and treatment of deep-vein thrombosis and growing awareness regarding thrombus complications are the major factors driving the market growth in Europe. For instance, according to the article published in National Center for Biotechnology Information (NCBI), deep vein thrombosis (DVT) is a healthcare burden in Europe. Furthermore, the Germany market of thrombus treatment held the largest market share, and the UK market of thrombus treatment is the fastest growing market in the Europe region. The Asia-Pacific thrombus treatment market is expected to grow at a significant share from 2024 to 2032. Owing to the presence of a diversified patient pool, the rising prevalence of deep vein thrombosis, and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as China and India are likely to boost the market in the Asia-Pacific region. Moreover, China market of thrombus treatment held the largest market share, and the India market of thrombus treatment is the fastest growing market in the Asia-Pacific region. ## **Thrombus Treatment Key Market Players & Competitive Insights** Major market players are spending a lot of money on R&D to increase their product lines, which will help the thrombus treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the thrombus treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment. Teva Pharmaceutical Industries Ltd. (Israel) is one of the leaders in the pharmaceutical industry engaged in developing and providing services for generic medicines. The company utilizes its arrangement of more than 1,800 molecules to create a wide variety of generic products in almost every therapeutic area. It specializes in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics. In June 2022, the company launched a generic version of apixaban oral anticoagulant that directly inhibits factor X, in UK. ### **Key Companies in the Thrombus Treatment Market Includes** **Thrombus Treatment Industry Developments** December 2021, Johnson & Johnson's (US) subsidiary Janssen Pharmaceutical Companies (Belgium) announced that the US Food and Drug Administration (FDA) had approved its two paediatric indications for XARELTO. In April 2021, The US Food and Drug Administration has granted AngioDynamics, Inc. (US) 510(k) clearance for its AlphaVac mechanical thrombectomy system. This allows for precise control of clot removal while minimizing patient blood loss. It has expanded the company's thrombus management portfolio, allowing it to serve the thrombectomy market. April 2018, Bristol-Myers Squibb Company (US) collaborated with Janssen Pharmaceuticals, Inc. (Belgium) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of BMS-986177, an investigational anticoagulant compound being studied for the prevention and treatment of major thrombotic conditions. ## **Thrombus Treatment Market Segmentation** ### **Thrombus Treatment Type Outlook** ### **Thrombus Treatment Treatment Outlook** ### **Thrombus Treatment Regional Outlook** ## Market Drivers ### Growing Geriatric Population The increasing geriatric population is a significant driver for the Thrombus Treatment Market. As individuals age, the risk of thrombotic events escalates due to various factors such as decreased mobility and the presence of comorbidities. According to demographic studies, the proportion of individuals aged 65 and older is projected to rise substantially in the coming decades, leading to a higher incidence of thrombus-related conditions. This demographic shift necessitates the development of specialized treatment protocols tailored to the needs of older patients. Healthcare providers are thus compelled to enhance their thrombus treatment offerings to cater to this vulnerable population. Consequently, the market is likely to expand as more resources are allocated towards research and development of age-appropriate therapies, ensuring that the needs of the aging population are adequately addressed. ### Advancements in Medical Technology Technological advancements in medical devices and treatment methodologies are significantly influencing the Thrombus Treatment Market. Innovations such as minimally invasive procedures, advanced imaging techniques, and robotic-assisted surgeries are transforming the way thrombus-related conditions are diagnosed and treated. For instance, the introduction of catheter-based thrombectomy devices has shown promising results in improving patient outcomes. According to industry reports, the market for thrombectomy devices is projected to grow at a compound annual growth rate of over 8% in the coming years. These advancements not only enhance the efficacy of treatments but also reduce recovery times, thereby attracting more patients to seek timely interventions. As technology continues to evolve, it is expected that the thrombus treatment market will witness further growth driven by these cutting-edge solutions. ### Increased Awareness and Screening Programs The growing awareness regarding thrombotic conditions and the importance of early detection is a crucial driver for the Thrombus Treatment Market. Public health initiatives and educational campaigns have been instrumental in informing individuals about the risks associated with thrombus formation. As a result, there has been a notable increase in screening programs aimed at identifying at-risk populations. For instance, the implementation of routine screening for deep vein thrombosis in high-risk patients has become more prevalent. This proactive approach not only aids in early diagnosis but also encourages timely treatment, thereby expanding the market for thrombus therapies. Furthermore, healthcare systems are increasingly recognizing the economic benefits of early intervention, which may lead to reduced healthcare costs in the long run. This trend is likely to bolster the demand for thrombus treatment options. ### Regulatory Support for Innovative Therapies Regulatory bodies are playing a pivotal role in shaping the Thrombus Treatment Market by providing support for the development and approval of innovative therapies. Recent initiatives aimed at expediting the approval process for new anticoagulants and thrombolytic agents have encouraged pharmaceutical companies to invest in research and development. For example, the introduction of fast-track designations for promising new treatments has led to a surge in clinical trials focused on thrombus management. This regulatory environment fosters innovation and enhances competition within the market, ultimately benefiting patients with more treatment options. As regulatory frameworks continue to evolve, it is anticipated that the thrombus treatment market will experience accelerated growth, driven by the introduction of novel therapies that address unmet medical needs. ### Rising Incidence of Cardiovascular Diseases The increasing prevalence of cardiovascular diseases is a primary driver for the Thrombus Treatment Market. As per recent data, cardiovascular diseases account for a substantial portion of global mortality rates, leading to heightened demand for effective thrombus treatments. The World Health Organization indicates that these diseases are responsible for approximately 31% of all deaths worldwide. This alarming statistic underscores the urgency for innovative treatment options, thereby propelling the thrombus treatment sector forward. Furthermore, the aging population is more susceptible to thrombotic events, which further amplifies the need for advanced therapeutic solutions. Consequently, healthcare providers are increasingly investing in research and development to address this growing health crisis, which is likely to enhance the market landscape for thrombus treatments. ## Future Outlook The Thrombus Treatment Market is projected to grow at a 6.57% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of thrombotic disorders, and rising healthcare expenditure. **New opportunities:** - Development of personalized thrombolytic therapies for targeted patient demographics. Expansion of telehealth services for remote thrombus management and monitoring. Investment in AI-driven diagnostic tools to enhance thrombus detection accuracy. By 2035, the Thrombus Treatment Market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Type: Atrial Thrombus (Largest) vs. Venous Thrombus (Fastest-Growing) In the Thrombus Treatment Market, Atrial Thrombus stands out as the largest segment due to its higher prevalence and association with conditions such as atrial fibrillation. This segment captures a significant share as the awareness and diagnosis of atrial thrombus increase among healthcare providers and patients alike. On the other hand, the Venous Thrombus segment is rapidly gaining traction, driven by a focus on venous thromboembolism and the development of new anticoagulant therapies that specifically target venous clots. The dynamic nature of this segment showcases a growing recognition of the need for effective treatments against venous thrombus formation. Atrial Thrombus (Dominant) vs. Venous Thrombus (Emerging) Atrial Thrombus represents the dominant force within the Thrombus Treatment Market, primarily driven by an aging population and the increasing incidence of atrial fibrillation. Its extensive treatment options, including novel anticoagulants and interventional procedures, cater to a wide range of patients, thereby solidifying its market position. Conversely, Venous Thrombus is emerging as a significant contender, particularly in the context of advancements in surgical techniques and rising awareness around deep vein thrombosis and pulmonary embolism. The rapid development of specialized drugs and improved diagnostic methods further reinforces the growth potential of Venous Thrombus, indicating a strong shift towards comprehensive care strategies in thrombus management. ### By Treatment: Medical Therapy (Largest) vs. Surgery (Fastest-Growing) In the Thrombus Treatment Market, 'Medical Therapy' holds the largest share, commanding the most significant attention from healthcare professionals and patients alike, primarily due to its non-invasive nature. This segment encompasses various pharmacological options that empower doctors to manage thrombus effectively without the need for surgical intervention, thus appealing to a broader demographic concerned with recovery times and treatment safety. Conversely, the 'Surgery' segment is witnessing accelerated growth, attributed to advancements in surgical techniques and technologies that enhance patient outcomes and reduce complications. This segment appeals primarily to patients with severe or complicated thrombus cases where immediate intervention is required. Medical Therapy (Dominant) vs. Surgery (Emerging) Medical Therapy in the Thrombus Treatment Market is characterized by its extensive variety of pharmacological interventions, including anticoagulants and thrombolytics, which provide effective management for patients. This segment has established itself as the preferred choice among clinicians, especially for those seeking non-invasive treatment approaches with a lower risk profile. On the other hand, the Surgery segment, although traditionally less favored due to its invasive nature, is emerging as a critical alternative driven by innovative surgical technologies and methods that improve accuracy and recovery times. Surgeons specializing in endovascular techniques are contributing to this segment's rapid expansion, making it a viable option for high-risk scenarios where immediate action is critical. ## Regional Market Share Analysis ### North America : Leading Market for Innovation North America is the largest market for thrombus treatment, accounting for approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of thrombotic disorders, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring rapid approval of innovative therapies and technologies. The United States leads the market, followed by Canada, with a competitive landscape featuring major players such as Johnson & Johnson, Pfizer, and Merck. These companies are actively involved in developing novel anticoagulants and thrombolytics, enhancing treatment options for patients. The presence of robust healthcare systems and a focus on patient-centric care further solidifies North America's position in the thrombus treatment market. ### Europe : Emerging Regulatory Frameworks Europe is a significant player in the thrombus treatment market, holding approximately 30% of the global share. The region benefits from a strong regulatory framework that encourages innovation and ensures patient safety. Countries like Germany and France are at the forefront, with increasing investments in healthcare technology and a rising incidence of thrombotic diseases driving demand for effective treatments. Leading countries in Europe include Germany, France, and the UK, where key players such as Bayer AG and Roche Holding AG are actively engaged in research and development. The competitive landscape is characterized by collaborations between pharmaceutical companies and healthcare providers, aimed at improving treatment outcomes. The European Medicines Agency continues to play a crucial role in facilitating the approval of new therapies, enhancing market growth. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is rapidly emerging as a key market for thrombus treatment, accounting for approximately 20% of the global share. The region's growth is fueled by increasing healthcare expenditure, a rising aging population, and a growing awareness of thrombotic disorders. Countries like China and India are witnessing significant demand for advanced treatment options, supported by government initiatives aimed at improving healthcare access. China is the largest market in the region, followed by Japan and India, with a competitive landscape featuring both local and international players. Companies such as Sanofi and AstraZeneca are expanding their presence, focusing on innovative therapies tailored to meet regional needs. The increasing prevalence of lifestyle-related diseases further drives the demand for effective thrombus treatments, positioning Asia-Pacific as a vital market for future growth. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa represent an emerging market for thrombus treatment, holding approximately 5% of the global share. The region is characterized by a growing healthcare infrastructure, increased investment in medical technologies, and a rising prevalence of thrombotic conditions. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at enhancing healthcare access and quality. South Africa is the largest market in the region, followed by the UAE, where key players are beginning to establish a foothold. The competitive landscape is evolving, with both multinational corporations and local firms seeking to address the unmet medical needs of the population. As awareness of thrombotic disorders increases, the demand for effective treatments is expected to rise, presenting significant opportunities for growth in the Middle East and Africa. ## Competitive Benchmarking Major market players are spending a lot of money on R&D to increase their product lines, which will help the thrombus treatment market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the thrombus treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment. Teva Pharmaceutical Industries Ltd. (Israel) is one of the leaders in the pharmaceutical industry engaged in developing and providing services for generic medicines. The company utilizes its arrangement of more than 1,800 molecules to create a wide variety of generic products in almost every therapeutic area. It specializes in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics. In June the company launched a generic version of [apixaban](https://www.marketresearchfuture.com/reports/apixaban-market-35175)oral anticoagulant that directly inhibits factor X, in UK. ## Recent News & Developments December 2021, Johnson & Johnson's (US) subsidiary Janssen Pharmaceutical Companies (Belgium) announced that the US Food and Drug Administration (FDA) had approved its two paediatric indications for XARELTO. In April 2021, The US Food and Drug Administration has granted AngioDynamics, Inc. (US) 510(k) clearance for its AlphaVac mechanical thrombectomy system. This allows for precise control of clot removal while minimizing patient blood loss. It has expanded the company's thrombus management portfolio, allowing it to serve the thrombectomy market. April 2018, Bristol-Myers Squibb Company (US) collaborated with Janssen Pharmaceuticals, Inc. (Belgium) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of BMS-986177, an investigational anticoagulant compound being studied for the prevention and treatment of major thrombotic conditions. ## Report Scope | MARKET SIZE 2024 | 40.27(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 42.92(USD Billion) | | MARKET SIZE 2035 | 81.11(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.57% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), Pfizer Inc. (US), Novartis AG (CH), Merck & Co., Inc. (US) | | Segments Covered | Type, Treatment, Region | | Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the Thrombus Treatment Market. | | Key Market Dynamics | Rising demand for innovative thrombus treatment solutions drives competitive dynamics and regulatory adaptations in the healthcare sector. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Thrombus Treatment Market?** A: As of 2024, the Thrombus Treatment Market was valued at 40.27 USD Billion. **Q: What is the projected market size for the Thrombus Treatment Market in 2035?** A: The Thrombus Treatment Market is projected to reach 81.11 USD Billion by 2035. **Q: What is the expected CAGR for the Thrombus Treatment Market from 2025 to 2035?** A: The expected CAGR for the Thrombus Treatment Market during the forecast period 2025 - 2035 is 6.57%. **Q: Which segments are included in the Thrombus Treatment Market?** A: The Thrombus Treatment Market includes segments such as Atrial Thrombus and Venous Thrombus under Type, and Medical Therapy, Surgery, and Others under Treatment. **Q: What were the valuations for Atrial and Venous Thrombus in 2024?** A: In 2024, Atrial Thrombus was valued at 16.08 USD Billion, while Venous Thrombus was valued at 24.19 USD Billion. **Q: How do the projected valuations for Atrial and Venous Thrombus compare in 2035?** A: By 2035, Atrial Thrombus is projected to reach 32.43 USD Billion, whereas Venous Thrombus is expected to grow to 48.68 USD Billion. **Q: What treatment options are available in the Thrombus Treatment Market?** A: Treatment options in the Thrombus Treatment Market include Medical Therapy, Surgery, and Others. **Q: What were the market valuations for Medical Therapy, Surgery, and Others in 2024?** A: In 2024, Medical Therapy was valued at 20.0 USD Billion, Surgery at 15.0 USD Billion, and Others at 5.27 USD Billion. **Q: What are the projected valuations for Medical Therapy, Surgery, and Others by 2035?** A: By 2035, Medical Therapy is projected to reach 40.0 USD Billion, Surgery to 30.0 USD Billion, and Others to 11.11 USD Billion. **Q: Who are the key players in the Thrombus Treatment Market?** A: Key players in the Thrombus Treatment Market include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Roche Holding AG, Sanofi S.A., AstraZeneca PLC, Pfizer Inc., Novartis AG, and Merck & Co., Inc. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/thrombus-treatment-market-11453*